Introduction
Since their introduction in early 1990s, selective 5-HT1B/1D agonists (triptans) have radically improved migraine management because of their effectiveness, tolerability and safety. Their use, despite the high cost, has largely increased in the last years. Five different compounds (sumatriptan, naratriptan, zolmitriptan, rizatriptan and almotriptan) are listed in the 2002 WHO-ATC list [1] and thus are clinically available in at least one market. Eletriptan and frovatriptan are two newer triptans, and a total of seven different compounds will be soon available for treatment of migraine patients.
Because of the large number of clinically available triptans, physicians need comparative clinical information to select those products with the highest likelihood of clinical success as well as comparative cost information to prefer, when possible, those products with the best cost-efficacy ratio. Even if several studies have demonstrated the costeffectiveness of triptans, their use leads to substantial costs and there is a need, in a capped budget era, to limit expenditures without affecting quality of care.
Despite several reports comparing clinical efficacy of triptans and a meta-analysis comparing 53 clinical trials [2] , no comparative data at the European level about triptan prices have been published and there is a gap of information at this level. Moreover, large price discrepancies between the European countries have been described for a variety of medicines. For all these reasons we thought it was of interest to compare costs of triptans and to study their price differentials.
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Materials and methods
Data were obtained from the EURO-Medicines database, a European Union-funded project aimed to collect information about medicines available in European countries and whose data are now available on the Internet (www.euromedicines.org). Details of the methodology and data sources used for collecting and analysing these data were provided elsewhere [3] .
Our comparison refers to prices in 2000 and is limited to solid oral triptan formulations, which are licensed in all the EU countries and are more commonly used. Thus, suppositories and parenteral forms (injection and spray) were excluded from the comparison. Prices were compared using the cost per single unit (tablet, capsule, wafer), calculated by dividing the retail (pharmacy) price of the pack by the number of single units. Retail price includes ex-factory (industry) price, wholesale margin, pharmacist margin and value added tax (VAT); the extent of these different components differs from country to country.
Retail prices were calculated in local currency and converted in euro using the fixed conversion rate
Swedish crowns and 0.63 British pounds). Incremental costs within countries were calculated assuming the cheapest price in each country as a reference.
Results
The lowest and highest prices, the countries with the lowest and highest prices and the percentage differences between countries are reported in Table 1 . The percentage differences between countries range, for a same compound, from 83% for rizatriptan (5 mg and 10 mg) to 140% for zolmitriptan (2.5 mg).
The triptans with the lowest price per unit by country are: naratriptan 2.5 mg in Belgium (€ 5.00) and UK (€ 6.35); zolmitriptan 2.5 mg in France (€ 4.69), Sweden (€ 5.88), UK (€ 6.35), Italy (€ 6.89) and Denmark (€ 7.52); and sumatriptan 50 mg in The Netherlands (€ 4.62), Sweden (€ 5.59, parallel import), and Germany (€ 7.95).
The incremental costs per single unit of the triptans and of their different strengths are reported in Table 2 . Naratriptan 2.5 mg is the least expensive triptan in Belgium and in the UK (together with zolmitriptan 2.5 mg in the UK). There are some important differences between these two countries: (1) the price per tablet of naratriptan in the UK (€ 6.35) is independent of pack size, while there is a 73% difference in Belgium according to the number of tablets in the pack; (2) the price of a zolmitriptan 2.5-mg unit is the same as that of a naratriptan 2.5-mg unit in the UK, while it is higher by 12%-86% in Belgium; (3) the price of rizatriptan 5 mg, compared with naratriptan 2.5 mg, is 11% higher in the UK and 97% higher in Belgium. Zolmitriptan 2.5 mg is the least expensive triptan in Denmark, France, Italy, UK and Sweden (Table 2 ). There are no major differences in the cost of a single zolmitriptan 2.5-mg unit between different pack sizes in the UK and Italy, while these prices vary by 19%, 24% and 26% in Sweden, France and Denmark, respectively. The cost of a sumatriptan 50-mg tablet, as compared with zolmitriptan 2.5 mg, is similar in Italy (1%) but differs by 18%-24% in the UK. The cost of a rizatriptan 5-or 10-mg unit is higher than that of zolmitriptan 2.5 mg by 11% in the UK, 1%-37% in Italy and 29%-39% in Denmark.
Discussion
From our data it appears that wide differentials in prices of triptans exist at a European Union level: the differences between countries for one compound range from 83% to 140% and they are not all in the same direction: the least expensive product in one country can be the most expensive in another country.
Moreover the extent of variations, excluding sumatriptan 100 mg, varies within countries from 24% in UK and France to 97% in Belgium. Including sumatriptan 100 mg the extent of variation becomes much wider, attaining 100% and 191% in the UK and Belgium, respectively.
Selection of the right triptan for an individual patient is a complex choice: it must take in consideration at least the clinical characteristics of the single patient (frequency and severity of migraine attacks, risk factors, contraindications to treatment), the efficacy of each triptan (pain-free response at 2 h, sustained pain-free rates, and recurrence rates), and the costs of treatment.
The wide price differentials mean that the most costeffective triptan can differ in Europe from country to country and this is a source of variation in the treatment of migraineurs. A better-harmonised European system of pricing could limit these unethical variations.
